SIGN UP
LOG IN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga·06/17/2025 12:08:52
Listen to the news
Gainers
- Acurx Pharmaceuticals (NASDAQ:ACXP) stock moved upwards by 235.5% to $1.03 during Tuesday's pre-market session. The company's market cap stands at $24.1 million.
- Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 82.37% to $1.14. The company's market cap stands at $2.4 million.
- Verve Therapeutics (NASDAQ:VERV) shares moved upwards by 75.93% to $11.03. The company's market cap stands at $983.3 million.
- Azitra (AMEX:AZTR) stock increased by 38.35% to $0.37. The company's market cap stands at $6.1 million.
- ProPhase Labs (NASDAQ:PRPH) shares moved upwards by 34.0% to $0.45. The market value of their outstanding shares is at $18.5 million.
- Prime Medicine (NASDAQ:PRME) shares increased by 16.66% to $1.75. The market value of their outstanding shares is at $229.7 million.
Losers
- Adial Pharmaceuticals (NASDAQ:ADIL) stock fell 34.8% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.8 million.
- Dyne Therapeutics (NASDAQ:DYN) shares decreased by 21.86% to $10.8. The company's market cap stands at $1.2 billion.
- Unicycive Therapeutics (NASDAQ:UNCY) shares declined by 20.66% to $0.6. The market value of their outstanding shares is at $72.1 million.
- Synaptogenix (NASDAQ:SNPX) shares decreased by 14.99% to $3.63. The market value of their outstanding shares is at $5.0 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock fell 11.06% to $0.3. The market value of their outstanding shares is at $7.2 million.
- Surgery Partners (NASDAQ:SGRY) stock decreased by 9.8% to $20.9. The market value of their outstanding shares is at $2.6 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.